Recruiting

BIOHM

Sponsor:

Case Comprehensive Cancer Center

Code:

NCT04362826

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Novel probiotic

Placebo

Study Details

Brief summary:

The purpose of this study is to examine the effect of probiotics on the breast tumor microbiome and gut microbiome in breast cancer. Microorganisms that make up the microbiome (such as viruses, bacteria, and fungi) may have an important role in breast cancer development. Understanding the association of microorganisms with breast cancer may enable new ways to prevent, diagnose, and treat breast cancer.

The probiotic, BIOHM, which is owned and distributed by BIOHM Health LLC, will be used in this study. BIOHM is a food supplement that is believed to balance bacteria and fungi in the body and has received the designation as Generally Recognized as Safe (GRAS) by the Food and Drug Administration (FDA). This study is being done to determine the effectiveness of BIOHM in breast cancer.

Conditions

Breast Cancer

Study ID

NCT04362826

Start date

Mar 20, 2026

Status verified date

Apr, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of breast cancer (invasive ductal carcinoma \[IDC\] or Invasive Lobular Carcinoma \[ILC\])
  • Minimum breast tumor size of 1.0 cm
  • Participants who are of childbearing potential must agree to use a medically approved method of birth control and have a negative pregnancy test result
  • BMI between 18.5 to 29.9 kg/m2
  • Agree to abstain from consuming unpasteurized bacteria-fermented foods one week prior to baseline visit and throughout the study.
  • Agree to not change current dietary habits (apart from avoiding probiotics) and activity/training levels one week prior to screening and during the study.
  • Agree to complete all research activities defined in the study
  • Participants must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Women who are pregnant, breast feeding, or planning to become pregnant during the trial.
  • Use of antibiotics within 5 weeks of randomization.
  • History of chronic inflammation or structural abnormality of the digestive tract (e.g., inflammatory bowel disease, duodenal or gastric ulcer intestinal obstruction, or symptomatic cholelithiasis).
  • Use of probiotic and/or prebiotic supplements and/or supplemented foods prior to screening and throughout the study.
  • Individuals receiving any other investigational agents within 30 days prior to randomization.
  • Change in anti-psychotic medication within 3 months prior to randomization.
  • Alcohol or drug abuse in the past year.
  • Participants with a known allergy to the test material's active or inactive ingredients..

Clinically significant abnormal laboratory results that may negatively impact the participant being involved on the study, at the discretion of the physician.

  • Any condition which in the investigators' opinions may adversely affect the participant's ability to complete the study or its measures or which may pose significant risk to the participant.
  • Physician feels participation in this trial is not in the subject's best interest.

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Novel probiotic

Investigational novel probiotic plus normal standard of care for breast cancer.

placebo comparator: Placebo

Placebo plus normal standard of care for breast cancer.

Interventions

Novel probiotic

Investigational novel probiotic

Placebo

Placebo for probiotic

Primary outcome measure

  • Beta-D-Glucagon levels [ Time Frame: At baseline and at 6 weeks ]
  • Short-chain fatty acid levels [ Time Frame: At baseline and at 6 weeks ]
  • Free amino acid levels [ Time Frame: At baseline and at 6 weeks ]

Central Contacts and Locations

Central contacts

Zahraa Al-Hilli, MD

+1 216-444-3440alhillz@ccf.org

Locations

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Recruiting

Cleveland, Ohio, United States, 44122

Contacts

Charis Eng, MD

+1 216-444-3440engc@ccf.org

Principal Investigator:

Charis Eng, MD, PhD, FACP

More Information

Sponsor

Case Comprehensive Cancer Center

Last update posted

Apr 9, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Case Comprehensive Cancer Center on 2026-04-09.